Fleming Initiative and LifeArc progress their first collaborative programme to strengthen antimicrobial stewardship
The Fleming Initiative, a partnership between Imperial College London and Imperial College Healthcare NHS Trust, and LifeArc, a self-funded medical research organisation has now progressed the first programme of work within the partnership, aimed at strengthening antimicrobial stewardship (AMS).
AMS aims to ensure that antimicrobial medicines, including antibiotics and antifungals, are used appropriately and remain effective for treating infections. It supports healthcare professionals through training, guidance and evidence-based approaches to make informed decisions about when and how these medicines are used. Imperial College Healthcare’s hospitals were the first in the UK to achieve Global Antimicrobial Stewardship Accreditation and designated a centre of excellence, meaning the partnership will benefit from this successful existing AMS stewardship programme.
The partnership aims to support a more proactive, evidence-based approach to AMS. Its longer-term ambition is to help translate advances in diagnostics, artificial intelligence (AI) and health data into approaches that support better-informed clinical decisions and more effective use of antimicrobial medicines.
Recognising that scientific and technological advances alone are not enough to improve stewardship, the partnership will also focus on the people, policies and health systems needed to make new approaches work in practice. This includes strengthening public engagement and involvement, sharing robust evidence with decision-makers, and building connections across research, healthcare and communities, with particular attention to African health systems.
The first programme of work will strengthen the Fleming Initiative’s public engagement and involvement work. This includes supporting the Fleming Initiative’s Public Advisory Group to ensure public perspectives inform and shape the Initiative’s work, and developing advocacy materials, practical toolkits and resources to support those working to involve the public in antimicrobial resistance (AMR) research and create meaningful opportunities for people to contribute their perspectives and lived experience.
The programme will also explore public understanding of AMR, including attitudes towards the use of diagnostics in tackling drug-resistant infections and support the sharing of patient stories to communicate the real-world impact of AMR.
Activities will build on engagement with local communities and strengthen connections between research, policy and practice.
A series of research activities will explore how evidence can be generated, translated and applied to strengthen AMS across diverse healthcare settings. Initial areas of focus include:
Using data analytics and AI to map AMS policies and interventions across countries, supporting comparison, evidence generation and shared learning.
Exploring how behavioural science can inform antimicrobial prescribing and how successful interventions can be adapted across different healthcare systems and contexts.
Further areas of work will be developed and prioritised jointly through the partnership as it evolves.
Professor Alison Holmes, Director of the Fleming Initiative, said:
“The Fleming Initiative was established to bring together research, clinical practice, policy and public engagement to tackle AMR. AMS is an area where we need stronger evidence and more effective ways to translate insights into practice. This is exactly where our integrated, convergent approach can make a difference.
“Our partnership with LifeArc will strengthen the AMR ecosystem’s capacity to engage with communities affected by AMR and at the frontline of AMS practice, build the evidence needed to inform practice, and understand how effective approaches can be adapted to different geographies.”
Dr Toby Leslie, Director, Global Health, Infection of LifeArc commented:
“AMR is a complex global challenge that cannot be solved by scientific innovation alone. Progress will depend on combining innovation with a deeper understanding of behaviour, health systems and people’s experiences.
“At LifeArc, we want new innovations to reach and benefit the people most affected by drug-resistant infections. Through our partnership with the Fleming Initiative, we are bringing together different perspectives and multidisciplinary expertise to help turn promising ideas into approaches that work to improve practice, with a focus on African health systems. This first programme will help put lived experience at the heart of innovation, so that future approaches are shaped around real-world needs and have the best chance of making a meaningful difference.”


